Coronary Archives

1-877-CSI-0360

Find A Doctor Contact Us Bioskills Lab Careers With Us

Product
Solutions
- Product Solutions
  For Healthcare
  Professionals
  
  At CSI, we are leading the way to help successfully treat arterial calcium by creating devices designed to restore blood flow and reduce calcium.
  
  Peripheral Interventions
  Peripheral Interventions
  Coronary Interventions
  Coronary Interventions
  Instructions for Use (IFU)
  Instructions for Use (IFU)
Healthcare
Professionals
- Healthcare
  Professionals
  
  Collaborating with leading experts to develop solutions to treat patients with advanced PAD and CAD.
  
  Physicians
  Physicians
  Fellows
  Fellows
  Cath Lab Team
  Cath Lab Team
  Hospital Administration
  Hospital Administration
  Clinical Evidence
  Clinical Evidence
  Case Studies
  Case Studies
  Healthcare Economics & Outcomes Research
  Healthcare Economics & Outcomes Research
  Reimbursement & Coding
  Reimbursement & Coding
Patient
Resources
- Patient
  Resources
  
  When you or a loved one is diagnosed with advanced CAD or PAD and include blockages made of calcium, you're looking for solutions. CSI is committed to getting people back to what matters.
  
  Peripheral Artery Disease (PAD)
  Peripheral Artery Disease (PAD)
  
  PAD is a potentially life-threatening disease where plaque, like calcium, builds up along blood vessel walls, narrowing the arteries and reducing blood flow to the legs and feet.
  
  Coronary Artery Disease (CAD)
  Coronary Artery Disease (CAD)
  
  Often referred to as blocked arteries, CAD is the most common heart disease and can cause shortness of breath, chest pain or a heart attack.
  
  Find a Doctor
  Find a Doctor
  
  Use our locator to find a doctor who is experienced using Cardiovascular Systems, Inc.'s (CSI) device to treat appropriate patients with PAD or CAD.
  
  PAD Patient Stories
  PAD Patient Stories
  CAD Patient Stories
  CAD Patient Stories
  Enter Your Zip Code
  Enter Your Zip Code
Investor
Relations
- Investor Relations
  
  Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating coronary and peripheral artery disease.
  
  Financial Events
  Financial Events
  
  Review SEC Filings, Financial Reports and Proxy Information.
  
  News Releases
  News Releases
  
  View our latest news, including financial announcements, clinical research results and product approvals and launches.
  
  Presentations
  Presentations
  
  Find information for investor presentations & earnings conference calls.
  
  Stock Information
  Stock Information
  
  Review current stock price, stock chart and analyst coverage.
  
  Stock Quote
  
  NASDAQ: CSII
  48.40
  +0.98 ( 2.07% )
  
  10/18/2019 11:57:17
  (Minimum 20 minutes delay)
About
CSI
- About CSI
  
  We are devoted to developing innovative solutions for treating peripheral and coronary artery disease, to help physicians conquer calcium, one of the largest challenges when treating PAD and CAD and help patients get back to what matters.
  
  Learn More
  Learn More
  
  Find out more about CSI, our company history, our solutions and the ways you can join in our efforts.
  
  Leadership
  Leadership
  
  The ability to serve the cardiovascular market with state-of-the-art medical technology begins with leaders.
  
  Careers
  Careers
  
  Learn more about what it's like to work at CSI, view open positions and apply.
  
  Media Resources
  Media Resources
  
  View our media kit and press releases, including financial announcements and clinical research results.
  
  Corporate Governance
  Corporate Governance
  
  Review our governance documents, principles of corporate governance and code of ethics and business conduct.
  
  Compliance
  Compliance
  
  Read about our company policies, monitoring, public disclosures and other details.

Blog

ECLIPSE: Evaluation of Treatment Strategies for Severe CaLcIfic Coronary Arteries: Orbital Atherectomy vs. Conventional Angioplasty Technique Prior to Implantation of Drug Eluting StEnts Purpose of the ECLIPSE Trial Severely...

Chris Wayne

25 May 2017

COAST

COAST was a prospective, multi-center study conducted in the U.S. and Japan that evaluated patients with severely calcified coronary lesions treated with the Diamondback 360® Coronary Orbital Atherectomy System (OAS) Micro...

Chris Wayne

25 May 2017

ORBIT II

The ORBIT II pivotal trial was a prospective, multi-center study conducted in the U.S. that evaluated patients with severely calcified coronary lesions treated with Diamondback 360® Coronary Orbital Atherectomy System...

Chris Wayne

1-877-CSI-0360

Product Solutions For Healthcare Professionals

Peripheral Interventions

Peripheral Interventions

Coronary Interventions

Coronary Interventions

Instructions for Use (IFU)

Instructions for Use (IFU)

Healthcare Professionals

Physicians

Physicians

Fellows

Fellows

Cath Lab Team

Cath Lab Team

Hospital Administration

Hospital Administration

Clinical Evidence

Clinical Evidence

Case Studies

Case Studies

Healthcare Economics & Outcomes Research

Healthcare Economics & Outcomes Research

Reimbursement & Coding

Reimbursement & Coding

Patient Resources

Peripheral Artery Disease (PAD)

Peripheral Artery Disease (PAD)

Coronary Artery Disease (CAD)

Coronary Artery Disease (CAD)

Find a Doctor

Find a Doctor

PAD Patient Stories

PAD Patient Stories

CAD Patient Stories

CAD Patient Stories

Enter Your Zip Code

Enter Your Zip Code

Investor Relations

Financial Events

Financial Events

News Releases

News Releases

Presentations

Presentations

Stock Information

Stock Information

Stock Quote

10/18/2019 11:57:17 (Minimum 20 minutes delay)

About CSI

Learn More

Learn More

Leadership

Leadership

Careers

Careers

Media Resources

Media Resources

Corporate Governance

Corporate Governance

Compliance

Compliance

Blog

ECLIPSE

25 May 2017

COAST

25 May 2017

ORBIT II

24 May 2017

Product Solutions
For Healthcare
Professionals

Healthcare
Professionals

Patient
Resources

10/18/2019 11:57:17
(Minimum 20 minutes delay)